Sánchez UJT

Idioma: Español
Referencias bibliográficas: 24
Paginas: 58-64
Archivo PDF: 249.29 Kb.

RESUMEN

El síndrome de apnea-hipopnea del sueño representa en la actualidad uno de los factores de riesgo más significativos para la enfermedad cardiovascular, desde ser considerado la segunda causa más frecuente de hipertensión arterial sistémica secundaria hasta ser un factor de riesgo para muerte súbita tanto en arritmias como en insuficiencia cardiaca. Es indispensable no sólo diagnosticar de manera adecuada el síndrome de apnea-hipopnea, sino más aún, caracterizarlo en forma apropiada, definir con claridad cuáles son los mecanismos etiológicos que la propician, tanto anatómicos como mecánicos, y realizar una cuantificación correcta. La presión positiva continua es un tratamiento útil para esta entidad, si bien tiene un serio problema de adherencia; hay que resaltar que no es el tratamiento ideal para todos los pacientes y que resulta indispensable hacer una indicación adecuada para cada una de las modalidades terapéuticas.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Javaheri S, Barbe F, Campos-Rodriguez F, Dempsey JA, Khayat R, Javaheri S et al. Sleep apnea: types, mechanisms, and clinical cardiovascular consequences. J Am Coll Cardiol. 2017; 69 (7): 841-858.

2. Lyons OD, Bradley TD. Heart failure and sleep apnea. Can J Cardiol. 2015; 31 (7): 898-908.

3. Cowie MR. Sleep apnea: state of the art. Trends Cardiovasc Med. 2017; 27: 280-289.

4. Dempsey JA, Veasey SC, Morgan BJ, O’Donnell CP. Pathophysiology of sleep apnea. Physiol Rev. 2010; 90: 47-112.

5. Sommers V, Javaheri S. Cardiovascular effects of sleep-related breathing disorders. In: Kryger MH, Roth T, Dement WC, editors. Principles and practice of sleep medicine. 6th edition. Philadelphia, PA: Elsevier; 2017. pp. 1243-1252.

6. Yaggi HK, Araujo AB, McKinlay JB. Sleep duration as a risk factor for the development of type 2 diabetes. Diabetes Care. 2006; 29: 657-661.

7. Peppard PE, Young T, Palta M, Skatrud J. Prospective study of the association between sleep-disordered breathing and hypertension. N Engl J Med. 2000; 342 (19): 1378-1384.

8. Nieto FJ, Young T, Lind BK. Association of sleep-disordered breathing, sleep apnea and hypertension in a large community-based study. Sleep Heart Health Study. JAMA. 2000; 283 (14): 1829-1836.

9. Gonçalves SC, Martinez D, Gus M, de Abreu-Silva EO, Bertoluci C, Dutra I et al. Obstructive sleep apnea and resistant hypertension: a case-control study. Chest. 2007; 132 (6): 1858-1862.

10. Minai OA, Ricaurte B, Kaw R, Hammel J, Mansour M, McCarthy K et al. Frequency and impact of pulmonary hypertension in patients with obstructive sleep apnea syndrome. Am J Cardiol. 2009; 104 (9): 1300-1306.

11. Arias MA, García-Río F, Alonso-Fernández A, Martínez I, Villamor J. Pulmonary hypertension in obstructive sleep apnoea: effects of continuous positive airway pressure: a randomized, controlled cross-over study. Eur Heart J. 2006; 27 (9): 1106-1113.

12. Fein AS, Shvilkin A, Shah D, Haffajee CI, Das S, Kumar K et al. Treatment of obstructive sleep apnea reduces the risk of atrial fibrillation recurrence after catheter ablation. J Am Coll Cardiol. 2013; 62 (4): 300-305.

13. Gami AS, Olson EJ, Shen WK, Wright RS, Ballman KV, Hodge DO et al. Obstructive sleep apnea and the risk of sudden cardiac death: a longitudinal study of 10,701 adults. J Am Coll Cardiol. 2013; 62 (7): 610-616.

14. Peker Y, Carlson J, Hedner J. Increased incidence of coronary artery disease in sleep apnoea: a long-term follow-up. Eur Respir J. 2006; 28 (3): 596-602.

15. Marin JM, Carrizo SJ, Vicente E, Agusti AG. Long-term cardiovascular outcomes in men with obstructive sleep apnoea-hypopnoea with or without treatment with continuous positive airway pressure: an observational study. Lancet. 2005; 365 (9464): 1046-1053.

16. McEvoy RD, Antic NA, Heeley E, Luo Y, Ou Q, Zhang X et al. CPAP for prevention of cardiovascular events in obstructive sleep apnea. N Engl J Med. 2016; 375 (10): 919-931.

17. Lanfranchi PA, Somers VK, Braghiroli A, Corrá U, Eleuteri E, Giannuzzi P. Central sleep apnea in left ventricular dysfunction: prevalence and implications for arrhythmic risk. Circulation. 2003; 107 (5): 727-732.

18. Oldenburg O, Wellmann B, Buchholz A, Bitter T, Fox H, Thiem U et al. Nocturnal hypoxaemia is associated with increased mortality in stable heart failure patients. Eur Heart J. 2016; 37 (21): 1695-1703.

19. Javaheri S, Caref EB, Chen E, Tong KB, Abraham WT. Sleep apnea testing and outcomes in a large cohort of Medicare beneficiaries with newly diagnosed heart failure. Am J Respir Crit Care Med. 2011; 183 (4): 539-546.

20. Cowie MR, Woehrle H, Wegscheider K, Angermann C, d’Ortho MP, Erdmann E et al. Adaptive servo-ventilation for central sleep apnea in systolic heart failure. N Engl J Med. 2015; 373 (12): 1095-1105.

21. Javaheri S. Pembrey’s dream: the time has come for a long-term trial of nocturnal supplemental nasal oxygen to treat central sleep apnea in congestive heart failure. Chest. 2003; 123 (2): 322-325.

22. Costanzo MR, Ponikowski P, Javaheri S, Augostini R, Goldberg L, Holcomb R et al. Transvenous neurostimulation for central sleep apnoea: a randomised controlled trial. Lancet. 2016; 388 (10048): 974-982.

23. Barbé F, Durán-Cantolla J, Sánchez-de-la-Torre M, Martínez-Alonso M, Carmona C, Barceló A et al. Effect of continuous positive airway pressure on the incidence of hypertension and cardiovascular events in nonsleepy patients with obstructive sleep apnea: a randomized controlled trial. JAMA. 2012; 307 (20): 2161-2168.

24. Peker Y, Glantz H, Eulenburg C, Wegscheider K, Herlitz J, Thunström E. Effect of positive airway pressure on cardiovascular outcomes in coronary artery disease patients with nonsleepy obstructive sleep apnea. The RICCADSA randomized controlled trial. Am J Respir Crit Care Med. 2016; 194 (5): 613-620.